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Abstract A novel serpin gene has been isolated, cloned and 
sequenced. A PCR amplified fragment of the gene was originally 
identified from human genomic DNA, and the full-length cDNA 
was subsequently isolated from HeLa cells and sequenced. The 
novel serpin is very high in protein sequence similarity (91.8%) 
to the squamous cell carcinoma antigen (SCCA), but contains 
substantial differences in the reactive site loop sequence, including 
a different amino acid (leucine) in the PI position. The gene 
product, named leupin, is expressed in HeLa cells, SKGIIIa cells 
and human placenta. The protein has a predicted M, of 44,857 
and an isoelectric point of 6.04 which is consistent with the more 
acidic form of SCCA associated with squamous cell carcinomas. 
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1. Introduction 
The serpins (serine protease inhibitors) are a superfamily of 
proteins comprising over 60 members from a wide range of 
organisms, and includes well-characterised plasma proteins 
such as ~-antitrypsin and antithrombin III [1,2]. The inhibitory 
specificity of serpins is largely determined by residues at the 
P~-P~' positions within the reactive site loop region which acts 
as a pseudo-substrate for the target protease [3]. Serpins also 
include proteins which lack protease inhibitory activity such as 
chicken ovalbumin, angiotensinogen and hormone binding 
globulins. A sub-family of serpins related to ovalbumin, the 
ov-serpins, has been identified based on higher sequence iden- 
tity (45 55%), gene organisation, and lack of an identifiable 
N-terminal signal sequence [4]. Human proteins belonging to 
this ov-serpin family include plasminogen activitor inhibitor-2 
(PAI-2) [5], leucocyte elastase inhibitor (LEI) [6], placental 
thrombin inhibitor (PTI) [7], and squamous cell carcinoma 
antigen (SCCA) [8]. 
SCCA is a component of the T-4 antigen protein which was 
isolated from human uterine cervical squamous cell carcinoma 
tissue and is used as a serum tumour marker for the manage- 
ment of squamous cell carcinomas [9,10]. The antigen is also 
expressed in normal squamous epithelial cells [11] and is associ- 
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ated with skin disorders such as psoriasis and eczema [12]. 
SCCA isolated from carcinoma of the cervix demonstrates het- 
erogeneity on isoelectric focussing, with normal squamous epi- 
thelia contairfing a predominantely neutral form and carcinoma 
tissue containing both neutral and acidic forms [13]. The gene 
encoding for SCCA has been cloned and sequenced from 
SKGII Ia cells, a uterine cervical carcinoma cell line [8]. The 
cleavage site of SCCA is Se~Ser which is unique to this serpin, 
and the protein has recently been shown to have inhibitory 
activity against cathepsin L and papain which are cysteine 
rather than serine proteases [14]. This cross-class inhibitory 
activity has previously been seen in the viral serpin crmA which 
inhibits the cysteine protease interleukin-1 fl-converting en- 
zyme (ICE) [15,16]. 
This study set out to look for novel ov-serpins by amplifying 
PCR fragments between two conserved regions in the human 
ov-serpins. Degenerate oligonucleotide primers to conserved 
sequences flanking the variable reactive site loop region were 
used. We describe a novel serpin gene, leupin which has been 
isolated from HeLa cell cDNA, and which is high in sequence 
similarity to the squamous cell carcinoma ntigen. 
2. Materials and methods 
2.1. Materials 
Oligonucleotide primers were synthesized and HPLC purified by 
Genosys, UK. MMLV reverse transcriptase and Taq polymerase were 
obtained from Promega. Dideoxy sequencing was performed using 
Sequenase, version 2.0, United States Biochemicals. SKGIIIa cells, a 
uterine cervical cancer epidermoid cell line [17] were kindly given by Dr. 
Shiro Nozawa, Keio University. 
2.2. PCR amplification of serpin fragments from human genomic DNA 
Human genomic DNA was prepared from whole blood [18], and used 
as a template for amplification of serpin fragments. The following 
degenerate oligonucleotide primers complementary to SCCA, PAI-2 
and EI sequences were synthesized: primer A: 5'-GGGGGATCCCC- 
NCGGTTCAAA(G/C)TNGAAGAG-3' (sense, corresponding to nu- 
cleotides 853-873 of SCCA and incorporating a BamHI restriction 
site); primer B: 5'-AAAAAGCTTCGGNGANGAA/GAATCTNCC- 
3' (antisense, corresponding to nucleotides 1153-1170 in SCCA, with 
HindIII site incorporated at 5' end). Amplification was carried out in 
a volume of 100 ¢tl with 1.5 mM MgC12, for 30 cycles of (94°C x 1.5 
min, 45°C x 1 min, and 72°C x 2 min). The product of 315 bp contain- 
ing a mixture of ov-serpin fragments was digested with BamHI and 
HindIII restriction enzymes and cloned into pBluescript KS +. Individ- 
ual inserts were subjected to dideoxy sequencing [19] using M13 for- 
ward and reverse primers. 
Abbreviations." SCCA, squamous cell carcinoma ntigen; PAI-2, plas- 
minogen activator inhibitor-2; LEI, leukocyte lastase inhibitor; PTI, 
placental thrombin inhibitor; RT-PCR, reverse transcription-polym- 
erase chain reaction. 
The sequence reported in this paper has been deposited in the EMBL 
database (Accession umber X89015, mRNA for leupin). 
2.3. Detection of leupin gene expression 
Expression of the leupin gene was examined by RT-PCR. Total RNA 
was isolated from a range of human cell lines and tissues using a 
phenol/guanidinium thiocyananate extraction method [20]. RNA (1 ¢tg) 
was reverse transcribed with MMLV-reverse transcriptase using 
random hexanucleotide primers [21]. PCR amplification of this first 
strand cDNA was performed with a specific oligonucleotide to leupin, 
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Fig. 1. PCR amplification strategy for isolation of ov-serpin fragments 
and for amplification of specific leupin and SCCA products. Primers 
A and B are degenerate sense and antisense primers based on the 
sequences of PAI-2, LEI and SCCA. Primers C and E are antisense 
primers to unique reactive site loop sequences of leupin and SCCA, 
respectively. Primer D is a sense primer to the 5' open reading frame 
sequence of SCCA and will also amplify from a leupin template. 
primer C. 5'-GGGGGTACCTGAAGGAGATGATAATCGAC-Y 
(antisense primer corresponding to nucleotides 1054-1071 in leupin, 
and incorporating a KpnI restriction endonuclease ite at the 5' end). 
Initial studies to detect expression used primer A with primer C which 
yielded a product of 219 bp (Fig. 1). 
2.4. Isolation of fulMength cDNA from HeLa cell RNA 
HeLa cell cDNA, prepared as described above, was used as a tem- 
plate to isolate the 5' end of the gene sequence. Primer D, 5'-GGGG- 
GATCCATGAATCACTCAGTGAAG-3' (sense primer correspond- 
ing to the 5' end of the SCCA open reading frame sequence, incorporat- 
ing a BamHI site) and primer B were used to amplify the full 1195 bp 
product, and primers D and C were used to amplify a specific 1094 bp 
leupin product (see Fig. 1). These fragments were restriction digested, 
cloned into Bluescript KS +, and dideoxy sequencing ofboth strands was 
carried out. To facilitate internal sequencing, products were further 
digested with HindlII (sites at positions 259 a~nd 766), and fragments 
were subcloned into Bluescript and subjected to dideoxy sequencing. 
M N S L S E A N T K F M F D L F Q Q F R K S 
ATG AAT TCA CTC AGT GAA GCC AAC ACC AAG TTe ATG TTC GAT CTG TTe CAA CAG TTC AGA AAA TCA 66 
D 
K E N N I F Y S P I S I T S A L G H V L L G A K 
AAA GAG AAC AAC ATC TTC TAT TCC CCT ATe  AGe ATe  ACA Tee  GCA TTA GGG ATG GTe CTe TTA GGA GCC AAA 138 
D N T A • Q I S K V L H F D 0 V T II N T T E K A 
GAC AAC ACT GCA CAA CAA ATT  AGe AAG GTT CTT CAC TTT  GAT CAA GTC Aee  GAG AAC ACC ACA GAA AAA GCT 210 
A T Y H V D R S O N V H H Q F Q K L L T E F N K 
GCA ACA TAT CAT GTT GAT AGG Tee GGA AAT GTT CAT CAC CAG TTT CAA AAG CTT CTG ACT GAA TTC AAC AAA 282 
S T D A Y E L K I A N K L F G E K T Y O F L Q E 
TCC ACT GAT GCA TAT GAG CTG AAG ATC GCC AAC AAG CTC TTC GOA GAA AAG ACG TAT CAA TTT TTA CAG GAA 354 
Y L D A I K K F Y Q T S V E S T D F A N A P E E 
TAT TTA GAT GCC ATC AAG AAA TTT TAC CAG ACC AGT GTG GAA TeT ACT OAT TTT GCA AAT GeT  Cee  GAA OAA 426 
S R K K I N S W V E S Q T N E K I K N L F P D O 
AGT CGA AAG AAG ATT  AAC TCC TGG GTG GAA AOT CAA ACG AAT GAA AAA ATT AA& AAC CTA TTT CCT GAT GGG 498 
T I G N D T T L V L V N A I Y F K O Q W R N K F 
ACT ATT GOC AAT OAT ACG Aee  CTG GTT CTT GTG AAC GCA ATe  TAT TTC AAA GGG CAG TOG GAG AAT AAA TTT $70 
Q Y N S F N F A L L E D V Q A K V L E I P Y K G 
CAA TAC AAT TCC TTT AAT TTT GCC TTG CTG GAG GAT GTA CAG GCC AAG GTC CTG GAA ATA Cee  TAC AAA GGC 714 
K D L S M I V L L P N R I D G L Q K L B B K L T 
AAA GAT CTA AGe ATG ATT  GTO CTG CTG CCA AAT GAA ATe  GAT GGT CTG CAG AAG CTT GAA GAG AAA CTC ACT 786 
A B K L M E W T S L Q N M R E T C V D L H L P R 
GeT GAG AAA TTO ATG GAA TGG ACA AOT TTG CAG AAT ATO AGA GAG ACA TOT GTC GAT TTA CAC TTA CCT C~ 058 
F K M E E S Y D L K D T L R T M G N V N I F N G 
TTC AAA A~G OJiA aAG AGC TAT GAC CTC AAG GAC ACG TTG AGA ACC ATG GGA ATG OTG AAT ATC TTC AAT GGG 930 
A 
D A D L S G M T W S H G L S V S K V L H K A F V 
GAT GCA GAC CTC Tee GGC ATG ACC TOG AGe CAC GOT CTC TeA GTA TCT AAA GTC eTA CAC AAG GCC TTT GTG 1002 
E V T E E G V E A A A A T A V V V V E L S S P S 
GAG GTC ACT GAG GAG GOA GTG GAA GeT GCA GCT GCC ACC GCT GTA GTA GTA GTC GAA TTA TCA TCT CCT TeA 1074 
C 
T N E B F C C N H P F L F P I R Q N K T N S I L 
ACT AAT GAA GAG TTC TOT TOT AAT CAC CCT TTC CTA TTC TTC ATA AGG CAA AAT AAG ACC AAC AGC ATC CTC 1146 
F Y G R F S S P 
TTC TAT GGC AGA TTC TCA TCC CCG 1170 
B 
K K R N T K E R K F W P N K N T Y K S V Q M M R 
AAA AAA GAA AAC ACT AAA GAG GAA AAA TTT TGG CCA AAC AAG AAT ACA TAC AAA TCT GTA CAG ATG ATG AGG 642 
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2.5. Expression of SCCA and leupin 
Further expression studies on human tissue were performed which 
detected a larger transcribed product of both SCCA and leupin. RT- 
PCR was carried out using the specific primer for leupin as described 
above or with a specific primer corresponding to the unique SCCA 
reactive site loop region sequence [8], primer E: 5" CCCCCGGGTA- 
CCTACGGGGATGAATCTG 3' (antisense tonucleotides 1054-1074 
in SCCA). In each case, amplification with the sense primer D to the 
5' open reading frame sequence was performed to yield a 1094 bp 
product. 
3. Results 
Sequence analysis of amplified ov-serpin fragments from 
human genomic DNA giave sequences of the known PAI-2, 
leucocyte lastase inhibitor and SCCA genes. The SCCA and 
LEI genes must therefore also contain this 315 bp 3' end of the 
open reading frame within the last exon as seen in the gene 
organisation of ovalbumin, gene Y and PAI-2 [22,23]. The 
fourth recognized ov-serpin, placental thrombin inhibitor was 
not amplified by the PCR primers used. 
In addition to the recognized sequences, a SCCA-like 315 bp 
sequence was also obtained which contained major differences 
with SCCA, particularly in the predicted reactive site loop 
protein sequence. In order to look for expression of this novel 
gene and to isolate the full-length cDNA, an oligonucteotide 
primer to the unique reactive loop sequence was used. RT-PCR 
with this primer (primer C) and with primer A produced the 
expected 219 bp sequence from HeLa cell RNA. To isolate the 
full-length predicted ov-serpin sequence, it was assumed that 
the high sequence similarity with SCCA might also extend to 
the 5' end of the gene. Thus a primer corresponding to the first 
18 nucleotides of the open reading frame of SCCA [8] was 
synthesized (primer D). Using the HeLa cell cDNA as a tem- 
plate, this yielded the expected product of 1195 bp with primer 
B, and nested PCR with primer C gave a 1094 bp product. 
Sequencing of these products gave the predicted open reading 
frame of the gene and protein sequence of the novel serpin (Fig. 
2). The nucleotide sequence is 95.3% identical to the SCCA 
gene (Accession o. $66896) and the protein sequence shows 
91.8% identity to SCCA (Fig. 3). The most concentrated region 
of divergence is the reactive site loop sequence which contains 
6 amino acid differences including the P1 amino acid. The novel 
protein has been named leupin due to the presence of a leucine 
residue at the Pl position. 
Previous studies on SCCA expression used a nucleotide 
probe to detect he transcribed gene [8]. Digoxygenin labelled 
probes for leupin and SCCA were synthesised from the individ- 
(-- 
Fig. 2. cDNA sequence and deduced protein sequence ofleupin. Under- 
lined regions indicate positions of PCR primers (from top, primer D, 
A, C and B). An original fragment of the gene was identified by ampli- 
fication from genomic DNA between regions A and B using degenerate 
primers based on the conserved sequences of SCCA, PAI-2 and LEI 
in these regions. Expression of the gene was examined using a specific 
oligonucleotide (primer C) to the unique reactive site loop sequence of
leupin. The full-length gene was obtained by amplification between 
primer B and primer D (based on SCCA sequence) using HeLa cell 
cDNA as a template. (Note that the given sequence ofthe underlined 
regions B and D is that of the incorporated oligonucleotide primers, 
and so the actual sequence may contain minor differences in these two 
regions.) 
1 RNSLSEANTKFMFD 
1 MNSLSEANTKFMFD 
N IFYSP  I $1TSALG 
N | FYSP  I $ I TSALG 
51 GO I KKVLHFDOVTE 
51 0 0 I~K V L H F D 0 V T E 
DRSGNVHHOFOKLL  
D R SG N V H H 0 F 0 K L L 
|01L  K | A N K L F G E K T Y L 
101L  K | A NK L FG E K T Y~ 
1~ FYOTSVESVDFANA 
1~ F Y 0 T S V E S~D F A N A 
161V E S 0 T N E K I K N L | P 
151V E $ 0 T N E K I K N L~P 
1~ LVNA I YFKGOWEKK 
1~ L V N A ) Y F K G 0 W E~K 
~1WPNKNTYKS 10MHR 
~1WP NK N T Y K $~0 M R R 
DVOAKVLE I PYKGK 
DVOAKVLE 1PYKGK 
~I  IDGLQKLEEKLTAE 
~11DGLOKLEEKLTAE 
276 RETRVDLHLPRF K V 
2~ RET~VDLHLPRF K~ 
~|  TMGMVDI  FNGDADL 
~1T R G R V~l  F N G D A DL  
SGVLHKAFVEVTEE 
S~V L H K A F V E V T E E 
~1GFGSSPASTNEEFH 
~1 ~S["~' -F I s  T N E E F~ 
376 N K T N $ I L F Y G R F S $ 
376 N K T N S I L F Y G R F S S 
L F 0 0 F R K S K E N $CCA 
L F 0 0 F R K S K E N Leupin 
M V L L G A K D N T A SCCA 
M V L L G A K O N T A Leupin 
N T T G K A A T Y H V SCCA 
N T TI"['IK A A T Y H V Leupin 
T E F NK S T D A Y E SCCA 
T E F N K S T D A Y E Leupin 
F L 0 E Y L D A 1K  K $CCA 
F L 0 [ Y L D A ! K K Leupln 
P E E S R K K I N S W SCCA 
P E E 5 R K K I N S 14 Leupin 
E G N I G S N T T L V SCCA 
['[~G['[']I G[i~-[~]T T L V Leupin 
F N K E D T K E E K F SCCA 
F['I~K E[l~T K E E K F Leupin 
0 Y T S F H F A S L E SCCA 
0 Y~]$  F[~]F AI'L"]L E Leupin 
D L S H I V L L P N E SCCA 
D L S M I V L L P N E Leupln 
K L M E WT $ L 0 N M 5CCA 
K L 11 E W T S L 0 N I'I Leupln 
E E S Y D L K D T L R SCCA 
tr E S Y D L K D T L R Leupln 
S G M T G SR G L V L SCCA 
S G R TI'~SI'R']G L~' -~ Leupln 
G A E A A A A T A V V SCCA 
G[V']E A A A A T A V V Leupin 
C N H P F L F F I R Q SCCA 
C N H P F L F F l R 0 Leupln 
P SCCA 
P Leup i n 
Fig. 3. Protein sequence alignment of leupin with SCCA. Amino acids 
which differ from the SCCA sequence are boxed. Leupin and SCCA 
share 95.3% nucleotide identity and 91.8% protein sequence identity. 
The reactive site loop sequence ontains 6amino acid differences within 
the 7 amino acids from P4 to P3' (351-357) including a leucine residue 
(L354) in the predicted Pj position. Specific primers to this region of 
both genes were used for RT-PCR expression studies. 
ual PCR products for use in Northern and Southern blot anal- 
ysis. Southern blots using high stringency conditions howed 
crossreactivity of the probes with both cDNA species (data not 
shown). Therefore RT-PCR with specific primers was used as 
the method of choice for examining individual expression of 
these genes. Oligonucleotide primers corresponding to the 
unique reactive site loop regions of leupin and SCCA were 
synthesized in order to detect such expression by RT-PCR. 
Both SCCA and leupin are expressed in HeLa cells, SKGIIIa 
cells and human placenta (Fig. 4). However, the relative levels 
of expression are different with greater amounts of SCCA ex- 
pressed in SKGIIIa cells (from which this gene was originally 
cloned) and with leupin showing higher levels of expression i  
HeLa cells and placenta than SCCA. 
4. Discussion 
A new serpin gene, leupin, has been identified using PCR 
between conserved regions of the ov-serpin subfamily of pro- 
teins. The gene product is expressed in human placenta nd in 
SKGlla and HeLa cell lines. The predicted protein shows high 
sequence similarity to the squamous cell carcinoma ntigen, is 
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identical in length to SCCA (390 aa) and has a predicted Mr 
of 44,857. There are 6 amino acid differences in the reactive 
loop sequence including the P~ position which is a leucine resi- 
due in leupin, compared to a serine residue in SCCA. These key 
differences imply that leupin is not merely as isoform of SCCA, 
but is likely to have a different arget protease or profile of 
target proteases. The two serpins represent a closer evolution- 
ary divergence than previously seen in mammalian serpins 
which generally show 30-50% sequence identity [24], and must 
represent a relatively recent gene duplication event. 
Alignment of the reactive site loop of leupin with other ser- 
pins (Fig. 5) shows a shared cleavage site with human a~- 
antichymotrypsin, an inhibitor of chymotrypsin and cathepsin 
G [25]. This would suggest that leupin may inhibit a chymotryp- 
sin-like protease. However, SCCA has recently been found to 
inhibit the cysteine proteases cathepsin-L and papain and 
showed no inhibitory activity against a wide range of serine 
proteases [14], so it is perhaps more likely that leupin will also 
show inhibitory activity against a cysteine protease. 
Purified SCCA has been shown to divide into two subgroups, 
an acidic form with pi<6.25, and a neutral form with a 
pI > 6.25. Monoclonal antibodies against seven epitopes recog- 
nised both forms of the antigen and one monoclonal antibody 
detected the acidic form only [10]. Further separation of SCCA 
by 2-D electrophoresis has shown 4 distinct spots [28]. This 
heterogeneity was assumed to be due to posttranslational mod- 
ification since Southern blot analysis of genomic DNA origi- 
nally suggested that only one copy of the gene was present [8], 
and there is some evidence that the most acidic spot is 
phosphorylated. However, our leupin sequence, which is also 
expressed in Hela and SKGI I Ia cells, may explain the presence 
of heterogeneity in SCCA protein preparations. Indeed, the 
protein sequences obtained from endopeptidase fragments 
which were used for primer design in isolating the original 
SCCA gene sequence [8], are identical in the leupin sequence. 
The higher levels of SCCA expression found by us in SKGI I Ia 
(a) 
1 2 3 4 $ 6 7 8 
bp 
1500 
600 
(b) 
bp 
1500 - 
1 2 3 4 $ 6 7 8 
00- 
Fig. 4. Expression of (a) leupin and (b) SCCA in human tissues. Total 
RNA was isolated and RT-PCR was performed using either antisense 
primers C (leupin) or primer E (SCCA) with sense primer D. Products 
were separated on 1% agarose and detected by ethidium bromide stain- 
ing. Lane 1 = 100 bp ladder; lane 2 = ECV 304 endothelial cells; lane 
3 = HeLa cells; lane 4 = SKGIIIa cells; lane 5 -- liver; lane 6 = pla- 
centa; lane 7 = small intestine; lane 8 = no template control. 
PI4 P I  P1 ' P7 ' 
I 1 I I I [ [ I I I I i J J i I I I I I P I I i 
G A E A A A A T A V V V V  E L S S P S T N E E F Leup in  
GAE A A A A T A V V G  FG S S P AS  T NEE F SCCA 
GT E AS  A A T A V  K I TL  L S ALV  E T RT  I AChT  
GT  E A A A G T  G G V M  TG n T GH G G P Q-  F PA I -2  
G S E A A A S  T A V V  I AG n S LNP  N RV T F AT I I I  
G R E V V G S A E A G V D A A S V - S - - E E F Ova l  
> < 
Fig. 5. Alignment of reactive site loop sequences of leupin with other 
serpins; SCCA = squamous cell carcinoma antigen [8], AChT = human 
~rantichymotrypsin [25], PAI-2 = plasminogen activator inhibitor-2 
[5], ATIII -- antithrombin II| [26], Oval = chicken ovalbumin [27]. The 
putative P[-PI' cleavage site of leupin deduced from this alignment is
LesSer, which is shared by human cq-antichymotrypsin. 
cells (Fig. 4) would favour the amplification and isolation of 
this cDNA species over that of leupin. The predicted isoelectric 
points of the unmodified proteins how leupin to have the lower 
pI of 6.04 which is consistent with the acidic form, whereas 
SCCA has a predicted pI of 6.63 consistent with the neutral 
form. Phosphorylated and dephosphorylated forms of both 
proteins could explain the presence of a total of 4 spots on 2-D 
electrophoresis. If this is the case, then previous biochemical 
and clinical studies on SCCA including the inhibition of cyste- 
ine proteases could be attributed to a mixture of SCCA and this 
second gene product, leupin. 
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